Skip to main content
Clinical Trials/CTRI/2025/11/097565
CTRI/2025/11/097565
Not yet recruiting
Post Marketing Surveillance

"To Evaluate Efficacy of Dexmedetomidine for Reducing Sucicnylcholine Induced Myalgia in Patients undergoing Electro convulsive Therapy."

Dhiraj Hospital Sumandeep vidyapeeth1 site in 1 country100 target enrollmentStarted: December 15, 2025Last updated:

Overview

Phase
Post Marketing Surveillance
Status
Not yet recruiting
Sponsor
Dhiraj Hospital Sumandeep vidyapeeth
Enrollment
100
Locations
1
Primary Endpoint
This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations and myalgia due to sucicnylcholine during electro convulsive therapy.

Overview

Brief Summary

In the present study we will be comparing the efficacy of low dose of intravenous Dexmedetomidine (0.25 mcg/ kg) diluted in 100 ml Normal Saline for reducing incidence and severity of sucicnylcholine induced myalgia and fascination and optimization of hemodynamics in patients undergoing electro convulsive therapy.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant and Outcome Assessor Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients willing to sign informed consent.
  • Patient belonging to ASA physical status 1 and
  • Patients undergoing Electroconvulsive therapy.

Exclusion Criteria

  • Patients unwilling to participate in study.
  • Patient with BMI more than 30 kg/m
  • Patient who are deaf or incapable of understanding the language.
  • Patients with history of allergy to an adrenergic agonist.
  • Pregnancy and lactating women.

Outcomes

Primary Outcomes

This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations and myalgia due to sucicnylcholine during electro convulsive therapy.

Time Frame: This prospective study will help us to evaluate the efficacy of low dose intravenous Dexmedetomidine in reducing fasciculations immediately after giving Sccinylcholine and myalgia due to sucicnylcholine after 60 minutes of electro convulsive therapy.

Secondary Outcomes

  • Effect of Dexmedetomidine in attenuating blood pressure & heart rate during electro convulsive therapy.(At Base line, 5 min after drug intervention, During ECT, 3 min, 5 min, 10 min, 20 min, 30 min after ECT)

Investigators

Sponsor
Dhiraj Hospital Sumandeep vidyapeeth
Sponsor Class
Private medical college
Responsible Party
Principal Investigator
Principal Investigator

DR SUCHETA SUHAS DOSHI

Smt Bhailal Kothari Shah Medical Institute and Research Centre Vadodara, Gujarat.

Study Sites (1)

Loading locations...

Similar Trials